Theriva™ Biologics to Present at the 2025 NeauxCancer Conference
Theriva™ Biologics (NYSE American: TOVX), a clinical-stage company focused on cancer therapeutics, has announced its participation in the upcoming NeauxCancer 2025 Conference in New Orleans. The event, organized by the Cancer Advocacy Group of Louisiana (CAGLA), will take place from March 27th-29th, 2025 at The Roosevelt New Orleans Hotel.
The company's management will deliver a presentation during the conference's Innovation track on Friday, March 28th at 9:00am. This track is dedicated to showcasing promising biotech and healthcare companies advancing oncology solutions. Additionally, Theriva's management team will be available for one-on-one meetings with interested investors during the conference.
Theriva™ Biologics (NYSE American: TOVX), un'azienda in fase clinica focalizzata sulle terapie per il cancro, ha annunciato la sua partecipazione alla prossima NeauxCancer 2025 Conference a New Orleans. L'evento, organizzato dal Cancer Advocacy Group of Louisiana (CAGLA), si svolgerà dal 27 al 29 marzo 2025 presso il The Roosevelt New Orleans Hotel.
La direzione dell'azienda presenterà un intervento durante il Innovation track della conferenza venerdì 28 marzo alle 9:00. Questo segmento è dedicato a mettere in mostra aziende biotech e sanitarie promettenti che stanno avanzando soluzioni in oncologia. Inoltre, il team di gestione di Theriva sarà disponibile per incontri one-to-one con investitori interessati durante la conferenza.
Theriva™ Biologics (NYSE American: TOVX), una empresa en etapa clínica enfocada en terapias contra el cáncer, ha anunciado su participación en la próxima NeauxCancer 2025 Conference en Nueva Orleans. El evento, organizado por el Cancer Advocacy Group of Louisiana (CAGLA), se llevará a cabo del 27 al 29 de marzo de 2025 en el The Roosevelt New Orleans Hotel.
La dirección de la empresa realizará una presentación durante la Innovation track de la conferencia el viernes 28 de marzo a las 9:00 a.m. Este segmento está dedicado a mostrar empresas biotecnológicas y de atención médica prometedoras que están avanzando en soluciones de oncología. Además, el equipo de gestión de Theriva estará disponible para reuniones individuales con inversores interesados durante la conferencia.
Theriva™ Biologics (NYSE American: TOVX)는 암 치료에 중점을 둔 임상 단계 회사로, NeauxCancer 2025 Conference에 참석할 것이라고 발표했습니다. 이 행사는 루이지애나 암 옹호 그룹(CAGLA)에서 주최하며, 2025년 3월 27일부터 29일까지 루이지애나주 뉴올리언스의 The Roosevelt New Orleans Hotel에서 개최됩니다.
회사의 경영진은 3월 28일 금요일 오전 9시에 Innovation track에서 발표를 할 예정입니다. 이 트랙은 온콜로지 솔루션을 발전시키는 유망한 생명공학 및 의료 회사를 소개하는 데 전념하고 있습니다. 또한, Theriva의 경영팀은 컨퍼런스 기간 동안 관심 있는 투자자와의 일대일 미팅을 위해 대기할 것입니다.
Theriva™ Biologics (NYSE American: TOVX), une entreprise en phase clinique axée sur les thérapies contre le cancer, a annoncé sa participation à la prochaine NeauxCancer 2025 Conference à La Nouvelle-Orléans. L'événement, organisé par le Cancer Advocacy Group of Louisiana (CAGLA), se déroulera du 27 au 29 mars 2025 à l'hôtel The Roosevelt New Orleans.
La direction de l'entreprise fera une présentation lors de la Innovation track de la conférence le vendredi 28 mars à 9h00. Ce segment est dédié à la mise en avant d'entreprises biopharmaceutiques et de santé prometteuses qui avancent des solutions en oncologie. De plus, l'équipe de direction de Theriva sera disponible pour des réunions individuelles avec des investisseurs intéressés durant la conférence.
Theriva™ Biologics (NYSE American: TOVX), ein Unternehmen in der klinischen Phase, das sich auf Krebstherapeutika konzentriert, hat seine Teilnahme an der kommenden NeauxCancer 2025 Conference in New Orleans angekündigt. Die Veranstaltung, die von der Cancer Advocacy Group of Louisiana (CAGLA) organisiert wird, findet vom 27. bis 29. März 2025 im The Roosevelt New Orleans Hotel statt.
Das Management des Unternehmens wird am Freitag, den 28. März um 9:00 Uhr eine Präsentation im Rahmen des Innovation track halten. Dieser Track ist darauf ausgerichtet, vielversprechende Biotech- und Gesundheitsunternehmen vorzustellen, die Lösungen in der Onkologie vorantreiben. Darüber hinaus wird das Management-Team von Theriva während der Konferenz für persönliche Gespräche mit interessierten Investoren zur Verfügung stehen.
- None.
- None.
ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company’s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.
A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas.
Theriva’s management team will be available for one-on-one meetings during the conference, interested investors should contact Theriva’s investor relations representative as below.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
For further information, please contact:
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When and where is Theriva Biologics (TOVX) presenting at the NeauxCancer 2025 Conference?
What is the focus of TOVX's presentation at the NeauxCancer 2025 Conference?
Can investors meet with Theriva Biologics management at the NeauxCancer Conference?
What type of company is Theriva Biologics (TOVX)?
